Assessment of thymidylate synthase expression in biopsy specimens and corresponding resection specimens of non-small-cell lung cancer

Histopathology

Volumn 61, Issue 3, 2012, Pages 465-472

  Herpel, Esther ^a   Schnabel, Philipp A ^a   Steins, Martin ^b   Dienemann, Hendrik ^b   Herth, Felix J F ^b   Thomas, Michael ^b   Schirmacher, Peter ^a   Warth, Arne ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Thoraxklinik Heidelberg ^*  (Germany)

Author keywords

Biomarker; Biopsy; Non small cell lung cancer; Prediction; Thymidylate synthase

Indexed keywords

PARAFFIN; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER PATIENT; CANCER SURGERY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENDOBRONCHIAL BIOPSY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CARCINOMA; LUNG LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TRANSBRONCHIAL BIOPSY; TRANSTHORACIC BIOPSY; TUMOR VOLUME;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; THYMIDYLATE SYNTHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84865361647     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04248.x     Document Type: Article

References (35)

1. Norman P. Pemetrexed disodium (Eli Lilly). Curr. Opin. Investig. Drugs 2001; 2; 1611-1622.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21; 2636-2644.
3. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22; 1589-1597.
4. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14; 253-263.
5. Gadgeel SM, Ruckdeschel JC, Patel BB et al. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J. Thorac. Oncol. 2011; 6; 927-933.
6. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. Thymidylate synthase gene variations: predictive and prognostic markers. Mol. Cancer Ther. 2009; 8; 1000-1007.
7. Righi L, Papotti MG, Ceppi P et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J. Clin. Oncol. 2010; 28; 1534-1539.
8. Nishimura R, Nagao K, Miyayama H et al. Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res. 1999; 19; 5621-5626.
9. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 2001; 19; 4298-4304.
10. Shiga H, Heath EI, Rasmussen AA et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin. Cancer Res. 1999; 5; 4097-4104.
11. Takamura M, Nio Y, Yamasawa K, Dong M, Yamaguchi K, Itakura M. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs 2002; 13; 75-85.
12. Takizawa M, Kawakami K, Obata T et al. Invitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol. Rep. 2006; 15; 1533-1539.
13. Ceppi P, Volante M, Ferrero A et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin. Cancer Res. 2008; 14; 1059-1064.
14. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107; 1589-1596.
15. Shintani Y, Ohta M, Hirabayashi H et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer 2004; 45; 189-196.
16. Hashimoto H, Ozeki Y, Sato M et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006; 106; 1595-1601.
17. Chang MH, Ahn JS, Lee J et al. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010; 69; 323-329.
18. Nakagawa T, Tanaka F, Otake Y et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002; 35; 165-170.
19. Shimokawa H, Uramoto H, Onitsuka T et al. TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer 2011; 72; 360-364.
20. Takeda M, Okamoto I, Hirabayashi N, Kitano M, Nakagawa K. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2011; 73; 103-109.
21. Takezawa K, Okamoto I, Okamoto W et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br. J. Cancer 2011; 104; 1594-1601.
22. Chen CY, Chang YL, Shih JY et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011; 74; 132-138.
23. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. World Health Organization classification of tumors. Pathology and genetics. Tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
24. Warth A, Muley T, Meister M et al. Loss of aquaporin-4 expression and putative function in non-small cell lung cancer. BMC Cancer 2011; 11; 161.
25. Kim SH, Kwon HC, Oh SY et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am. J. Clin. Oncol. 2009; 32; 38-43.
26. Lindebjerg J, Nielsen JN, Hoeffding LD, Jakobsen A. Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. APMIS 2005; 113; 600-602.
27. Nakagawa T, Otake Y, Yanagihara K et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004; 43; 145-149.
28. Watanabe S, Watanabe R, Oton-Leite AF et al. Analysis of cell proliferation and pattern of invasion in oral squamous cell carcinoma. J. Oral Sci. 2010; 52; 417-424.
29. Chu E, Koeller DM, Casey JL et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc. Natl Acad. Sci. USA 1991; 88; 8977-8981.
30. Huang CL, Liu D, Nakano J et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin. Cancer Res. 2007; 13; 6938-6946.
31. Navalgund LG, Rossana C, Muench AJ, Johnson LF. Cell cycle regulation of thymidylate synthetase gene expression in cultured mouse fibroblasts. J. Biol. Chem. 1980; 255; 7386-7390.
32. Derenzini M, Montanaro L, Trere D et al. Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. Mol. Pathol. 2002; 55; 310-314.
33. Takezawa K, Okamoto I, Tsukioka S et al. Identification of thymidylate synthase as a potential therapeutic target for lung cancer. Br. J. Cancer 2010; 103; 354-361.
34. Ehrnrooth E, von der Maase H, Sorensen BS, Poulsen JH, Horsman MR. The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells invivo. Int. J. Radiat. Biol. 1999; 75; 885-891.
35. Gosens MJ, Moerland E, Lemmens VP, Rutten HT, Tan-Go I, van den Brule AJ. Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int. J. Cancer 2008; 123; 1941-1949.